New Ultrasound Platform for Cerebral Blood Flow Measurements

The NovaGuide 2 Platform, comprised of the NovaGuide 2 Intelligent Ultrasound and NovaGuide View cloud-based  software, provides critical, real-time information about cerebral blood flow to guide patient diagnosis and treatment. The new solution launched by  NovaSignal Corporation  is designed to seamlessly integrate into existing clinical practice .

Using NovaSignal’s FDA-cleared, CE-marked, robotic ultrasound technology, the NovaGuide 2 Intelligent Ultrasound is a unified, AI-driven cerebral ultrasound solution that autonomously captures blood flow data to identify brain illnesses and disease. NovaGuide 2 incorporates advanced algorithms, features an intuitive design, and delivers an efficient exam experience to speed time to diagnosis and treatment.

“The automated NovaGuide broadens our capabilities to treat ruptured aneurysm patients by giving us the ability to monitor for vasospasm any time of the day or night,” said Dr. Chirag Gandhi, Director of Neurosurgery at Westchester Medical Center. “The technology also eliminates inter-operator variability in ultrasound assessments and ensures that any change such as emboli or reduced blood flow are monitored, allowing me to stay updated on patient status.”

Populated with data from NovaGuide, the cloud-based NovaGuide View enables faster time to treatment with on- demand access to dynamic exam data. The interactive application improves coordination of clinical teams and reduces time to intervention with secure access to exam snapshots, videos, audio, and reports. Designed by data security experts, NovaGuide View ensures NovaGuide 2 Intelligent Ultrasound data is uploaded and stored in a secure, HIPAA-compliant cloud for instant viewing on the personal devices of the clinical team.

“Technology, data, and AI are transforming the way care is administered, resulting in improved patient outcomes. Cerebral blood flow data collected through our AI-driven, robotic ultrasound system is of tremendous value to clinical teams as they strive to reduce time to treatment,” said NovaSignal chairman and CEO, Diane Bryant. “Our technology allows them to easily and rapidly identify the existence of stroke-causing events by providing a direct view into the brain. The mission of NovaSignal is to unlock the power of blood flow data.”